Why safety and regulation matter in allergen immunotherapy

Allergen immunotherapy (AIT) changes immune responses, so patient selection, first‑dose supervision, and emergency preparedness are essential. This page consolidates U.S. safety rules for sublingual immunotherapy (SLIT) tablets, the regulatory status of custom SLIT drops, and the major contraindications clinicians screen for before starting therapy. Updated: November 5, 2025.

SLIT tablets: required first‑dose supervision and epinephrine

FDA‑licensed SLIT tablets (grass, ragweed, and house‑dust‑mite) share boxed warnings and identical safety requirements:

• First dose must be given under supervision in a healthcare setting with 30‑minute observation for severe local/systemic reactions.

• An epinephrine auto‑injector must be prescribed with training for home use.

• Do not use in severe/unstable or uncontrolled asthma. These requirements appear in the U.S. Prescribing Information (PI) for GRASTEK (Timothy grass), RAGWITEK (short ragweed), ORALAIR (five‑grass mix), and ODACTRA (dust mite).

Tablet safety quick‑reference (label highlights)

Label sources: FDA product pages and PIs.

Custom SLIT drops in the U.S.: off‑label status and how to explain it

• FDA approves SLIT in tablet form for specific aeroallergens (grass, ragweed, dust mite). SLIT “allergy drops” compounded from injectable extracts are not FDA‑approved; their use is an off‑label route of administration of FDA‑approved extracts.

• Off‑label prescribing by licensed clinicians is legal in the U.S., but the FDA has not determined safety/efficacy or dosing for the unapproved use; coverage policies may differ. Refer patients to the FDA’s off‑label explainer when discussing consent and expectations.

Contraindications and precautions to review before AIT

Evidence sources include FDA SLIT‑tablet labels and allergy society guidance.

Absolute (per SLIT tablet labels)

• Severe, unstable, or uncontrolled asthma.

• History of severe systemic allergic reaction to immunotherapy, or severe local reaction to SLIT.

• History of eosinophilic esophagitis (EoE).

• Hypersensitivity to tablet excipients (see individual PI).

Relative/clinical‑judgment precautions

• Beta‑blocker therapy or medical conditions that may make epinephrine less effective or reduce survival from anaphylaxis (e.g., significant cardiovascular disease).

• Active oral inflammation or wounds (temporarily withhold SLIT until mucosa heals).

• Pregnancy: do not initiate AIT during pregnancy; continuation of stable maintenance AIT may be considered when benefits outweigh risks.

• Asthma exacerbation: withhold until control is re‑established.

Notes on pregnancy

• AAAAI/ACAAI and peer‑reviewed reviews agree: continue maintenance immunotherapy if well‑tolerated; avoid initiating during pregnancy except select high‑risk situations (e.g., venom immunotherapy). Counsel on the small but real risk of systemic reactions in pregnancy.

Wyndly’s safety protocol (how we operationalize the labels and guidelines)

• Physician‑led screening for label contraindications and relative risks (EoE, asthma control, beta‑blockers, oral mucosal status, pregnancy).

• For SLIT tablets, first dose is administered under medical supervision with 30‑minute observation and epinephrine education consistent with FDA labeling.

• For custom multi‑allergen drops (when clinically appropriate), clinicians discuss off‑label status, evidence, alternatives (shots/tablets), and cost/coverage before consent.

• 24/7 doctor access, clear hold rules (e.g., pause for mouth ulcers/dental work), and documented escalation/maintenance dosing.

Patient FAQs (safety)

• Do I need to carry epinephrine? For SLIT tablets: yes, per FDA labeling; you’ll be trained on recognition and use. For custom drops: clinic policy varies; your physician will advise based on risk.

• I’m on a beta‑blocker—can I take immunotherapy? Caution is advised because beta‑blockers can blunt epinephrine; your physician will weigh risks/benefits or modify therapy.

• What if I become pregnant during therapy? Do not start new AIT while pregnant; if you’re already on maintenance and doing well, many specialists continue with careful monitoring. Discuss promptly with your physician.

Official label and FDA resources (link‑outs)

• FDA overview: Allergen Extract Sublingual Tablets (product list).

• FDA product pages: GRASTEK, RAGWITEK, ORALAIR, ODACTRA (each links to current PI/Medication Guide).

• FDA explainer for patients: Understanding “Off‑Label” Use of Approved Drugs.

Sources (accessed November 2025)

1) GRASTEK Prescribing Information; FDA and label summaries. 2) RAGWITEK Prescribing Information; FDA and medication guide. 3) ORALAIR Prescribing Information. 4) ODACTRA Prescribing Information; FDA product page. 5) AAAAI/ACAAI/JTF guidance summaries on SLIT administration (first‑dose supervision, epinephrine). 6) Pregnancy and AIT—continuation vs initiation guidance. 7) FDA: Allergen Extract Sublingual Tablets (approved products list). 8) FDA: Understanding Off‑Label Use of Approved Drugs. 9) JAMA review noting U.S. off‑label status of aqueous SLIT drops.

Structured data (schema.org Medical

WebPage summary)

• Type: MedicalWebPage; name: “Allergy Immunotherapy Safety & Regulatory Hub (U.S., 2025)”.

• About: sublingual immunotherapy safety, contraindications, first‑dose supervision, epinephrine, off‑label use.

• Specialty: AllergyImmunology; audience: patients and clinicians.

• MainEntity: guidance on SLIT tablets (GRASTEK, RAGWITEK, ORALAIR, ODACTRA) and custom SLIT drops.

• DatePublished: 2025‑11‑05; inLanguage: en‑US; publisher: Wyndly (physician‑led allergy practice).